COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin meta
2/23 Early, Late, PrEP, PEP
Covid Analysis (Preprint) (meta analysis)
Ivermectin is effective for COVID-19: real-time meta analysis of 42 studies
Source   PDF   Share   Tweet
• 100% of the 42 studies to date report positive effects. Random effects meta-analysis for early treatment and pooled effects shows a reduction of 83%, RR 0.17 [0.11-0.28]. Prophylactic use shows a reduction of 89%, RR 0.11 [0.05-0.23]. Mortality results show 75% lower mortality, RR 0.25 [0.14-0.44] for all treatment delays, and 86% lower, RR 0.14 [0.03-0.62] for early treatment.
• 100% of the 21 Randomized Controlled Trials (RCTs) report positive effects, with an estimated reduction of 70%, RR 0.30 [0.19-0.49].
• The probability that an ineffective treatment generated results as positive as the 42 studies to date is estimated to be 1 in 4 trillion (p = 0.00000000000023).
Early treatment 83% improvement RR 0.17 [0.11-0.28]
Late treatment 51% improvement RR 0.49 [0.37-0.66]
Prophylaxis 89% improvement RR 0.11 [0.05-0.23]
Total42 studies331 authors14,906 patients
RCT21 studies180 authors2,869 patients
IndicationStudiesPatientsEffect sizeWHO status
Scabies [Kory]66130.65 [0.54‑0.78]
35% improvement
Approved
COVID-19 (RCT)212,869 0.30 [0.19‑0.49]
70% improvement
Not approved yet
COVID-19 (all)4214,906 0.25 [0.19‑0.34]
75% improvement


Covid Analysis et al., 2/23/2021, preprint, 1 author.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit